# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 1...
56.4% major response rate exceeded 20% primary endpoint · 98.2% disease control rate achieved in heavily pretreated pati...
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, developmen...